TP53 and cancer: Consistent with its initial discovery using the survivin promoter-driven luciferase reporter system as a biomarker/target, and the data shown in the Figures 1–, 3, FL118 selectively inhibited human survivin promoter-driven luciferase activity at concentrations as low as 0.1–1 nM in various cancer cell types regardless of p53 status (Fig. 4a, b).